Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

What We're Reading

A Sampling of Highlights from the Literature

Article Recommendations from our Deputy and Senior Editors

DOI:  Published October 2018
  • Article
  • Info & Metrics
  • PDF
Loading

Identification of non-mutated neoantigens presented by TAP-deficient tumors


Embedded Image

Identifying unmutated neoantigens (from Fig. 1 of Marijt et al., J Exp Med 2018)

TAP-deficient tumor cells generate nonmutated antigens derived from N-terminal signal peptides or C-terminal tail peptides, to which multiple individuals can have reactive T cells. These T cells are activated by peptides from TAP-deficient tumors of diverse tissue origins. Targeting these antigens does not harm critical organs expressing the intact protein, thereby providing a therapeutic opportunity for TAP-deficient tumors that escape immune surveillance.

Marijt KA, …, van Hall T. J Exp Med 2018 Aug 16. DOI: 10.1084/jem.20180577.

Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function


Embedded Image

Strong activation signals can affect downstream cellular effects (by Krish Dulal via Wikimedia Commons)

Signal strength trumps signal type. Head-to-head comparison of the downstream phosphorylation patterns in T cells activated by CARs containing either CD28 or 4-1BB signal domains suggested they are almost identical. However, the CD28 domains led to stronger TCR signals that led to faster and larger magnitude downstream phosphorylation, leading to more effector differentiation and less memory formation, making the cells less effective at eliminating axenografted lymphoma in a mouse model.

Salter AI, …, Riddell SR. Sci Signal 2018 Aug 21;11:eaat6753.

Major role for IL1 in CAR T-cell CRS and neurotoxicity


Embedded Image

Neurotoxicity after CAR T-cell therapy (from Fig. 2 of Santomasso et al., CD2018)

Two teams developed new mouse models to examine the cytokine-release syndrome (CRS) experienced by patients treated with CAR T cells. Both find that IL6 and IL1 from monocytes and macrophages are the major effectors of the toxicity. Giavridis et al. developed a CAR that produced IL1Ra (IL1 receptor antagonist), which obviated CRS without diminishing T-cell antitumor efficacy.The Norelli group's model recapitulates aspects of the neurotoxicity associated with human CRS and finds that, although IL6 and IL1 from macrophages are both involved in CRS, blocking signals from the IL1R alone can prevent neurotoxicity. Santomasso et al. evaluate this in treated patients and show that the neurotoxic effects are likely due, in part, from nervous system–specific production of IL6, IL8, IP10, and MCP1. Seizures appear likely due to excitatory agonists present in the cerebrospinal fluid, and are mediated by quinolinic acid and glutamate-activated NMDA and AMPA receptors.

Norelli M, …, Bondanza A. Nat Med 2018 May 28;24:739–48.

Giavridis T, …, Sadelain M. Nat Med 2018 May 28;24:731–8.

Santomasso BD, …, Brentjens RJ. Cancer Discov 2018 Aug 1;8:958–71.

Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases


Embedded Image

Pancreatic adenocarcinoma (by Ed Uthman via Wikimedia Commons)

A mouse model was developed to examine why dormant micrometastases arise in PDA and become active after resection of pancreatic ductal adenocarcinomas. Hosts with PDA contain disseminated cancer cells (DCCs) that do not express cytokeratin or MHC class I, which is needed for an adaptive immune response. These DCCs are experiencing a cell autonomous ER stress response promoting a dormant state. If the stress response is resolved by expression of XBP1s and T cells are also depleted, class I and cytokeratin are re-expressed, and micrometastases grow into macrometastases.

Pommier A, …, Fearon DT. Science 2018 Jun 15;360:eaao4908.

High-dimensional single cell analysis identifies stemlike cytotoxic CD8+ T cells infiltrating human tumors


Embedded Image

High-dimensional single-cell analysis of TILs (from Fig. 1 of Brummelman et al., J Exp Med 2018)

Tumor-infiltrating CD8+ T cell subsets have not yet been fully defined. Brummelman et al. used high-dimensional single-cell analysis of tumors, blood, and normal tissues from 53 patients with non–small cell lung cancer to identify specific CD8+ T cell subsets enriched in the tumor microenvironment. A subset of CXCR5+TIM-3− partially exhausted CD8+ T cells expressing PD-1 and TIGIT were found and shown to have stem-like characteristics, including self-renewability and multipotency, while also maintaining effector potential. As disease progresses, this subset disappears and outcomes worsen.

Brummelman J, …, Lugli E. J Exp Med 2018 Aug 28. DOI: 10.1084/jem.20180684.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti–PD-1 response


Embedded Image

Release of exosomes expressing PD-L1 (by John Liu via Wikimedia Commons)

A mechanism of immune evasion is tumor cell upregulation of PD-L1, which interacts with PD-1 to deliver suppressive signals to T cells. Chen et al. demonstrate metastatic melanoma releases exosomes expressing PD-L1, which increases after exposure to IFNγ, and can suppress antitumor responses and facilitate tumor growth. Assessment of exosomal PD-L1 stratified melanoma patients into responders and non-responders to PD-1 blockade, highlighting that this may be useful as a biomarker for predicting outcomes with anti–PD-1 therapy.

Chen G, …, Guo W. Nature 2018 Aug 8;560:382–386.

  • ©2018 American Association for Cancer Research.
Next
Back to top
Cancer Immunology Research: 6 (10)
October 2018
Volume 6, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Sampling of Highlights from the Literature
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Sampling of Highlights from the Literature
Cancer Immunol Res October 1 2018 (6) (10) 1121;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Sampling of Highlights from the Literature
Cancer Immunol Res October 1 2018 (6) (10) 1121;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Identification of non-mutated neoantigens presented by TAP-deficient tumors
    • Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
    • Major role for IL1 in CAR T-cell CRS and neurotoxicity
    • Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases
    • High-dimensional single cell analysis identifies stemlike cytotoxic CD8+ T cells infiltrating human tumors
    • Exosomal PD-L1 contributes to immunosuppression and is associated with anti–PD-1 response
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • A Sampling of Highlights from the Literature
  • A Sampling of Highlights from the Literature
  • A Sampling of Highlights from the Literature
Show more What We're Reading
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement